TABLE 1.
Susceptibilities to tigecycline among Gram-negative isolates from unique patients as determined by various testing methodologiesa
| Organism (n) | Susceptibility of isolates (no. [%]), determined by: |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Etest |
BMDb |
MicroScan |
Vitek-2 |
|||||||||
| Susceptible | Intermediate | Resistant | Susceptible | Intermediate | Resistant | Susceptible | Intermediate | Resistant | Susceptible | Intermediate | Resistant | |
| A. baumannii (1,105) | 436 (40.3) | 515 (47.6) | 132 (12.2) | 956 (88) | 109 (10) | 21 (1.9) | 1,009 (93.2) | 56 (5.2) | 18 (1.7) | 643 (63.9) | 311 (31.1) | 50 (5) |
| ESBL-producing Enterobacteriaceaec (2,065) | 1,979 (96.4) | 66 (3.3) | 8 (0.3) | 2,008 (98.1) | 33 (1.6) | 5 (0.2) | 2,024 (98.7) | 25 (1.2) | 2 (0.1) | 1,781 (96.3) | 38 (2) | 32 (1.8) |
| CREd (369) | 291 (79.3) | 70 (19) | 6 (1.7) | 336 (91.6) | 23 (6.3) | 8 (2.1) | 331 (90.7) | 29 (7.9) | 5 (1.4) | 264 (78.8) | 29 (8.7) | 42 (12.6) |
| Susceptible Enterobacteriaceae (888) | 844 (96.8) | 24 (2.7) | 4 (0.4) | 855 (98.2) | 11 (1.3) | 5 (0.6) | 854 (98.8) | 10 (1.2) | 0 | 665 (97.5) | 4 (0.6) | 13 (1.9) |
a
n = 4,427.
b
BMD, broth microdilution.
c
ESBL, extended-spectrum β-lactamase.
d
CRE, carbapenem-resistant Enterobacteriaceae.